BIOC - Biocept Inc Stock Price, Fair Value and News

0USD0Market Closed

BIOC Stock Price

View Fullscreen

BIOC RSI Chart

BIOC Valuation

Market Cap

183.8K

Price/Earnings (Trailing)

-0.01

Price/Sales (Trailing)

0.01

EV/EBITDA

0.22

Price/Free Cashflow

-0.01

BIOC Price/Sales (Trailing)

BIOC Profitability

Free Cashflow Yield

-9.9K%

BIOC Fundamentals

BIOC Revenue

BIOC Earnings

Breaking Down BIOC Revenue

Last 7 days

-40%

Last 30 days

-50%

Last 90 days

-97.9%

Trailing 12 Months

-66.9%

How does BIOC drawdown profile look like?

BIOC Financial Health

BIOC Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	63.4M	57.2M	40.7M	25.9M
2021	43.8M	54.9M	65.8M	61.2M
2020	6.0M	5.7M	10.7M	27.5M
2019	3.5M	3.8M	4.6M	5.5M
2018	4.2M	3.7M	3.4M	3.3M
2017	4.7M	5.3M	5.4M	5.1M
2016	681.3K	1.3M	2.1M	3.2M
2015	223.0K	312.7K	467.2K	609.9K
2014	134.1K	133.9K	133.6K	133.4K
2013	134.1K	128.4K	136.4K	134.2K
2012	0	0	0	109.3K

Get all data in R, Python etc through our Historical Stock Data APIs

About Biocept Inc

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

CEO	Mr. Antonino Morales
WEBSITE	https://biocept.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	50

Biocept Inc Frequently Asked Questions

What is the ticker symbol for Biocept Inc? What does BIOC stand for in stocks?

BIOC is the stock ticker symbol of Biocept Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biocept Inc (BIOC)?

As of Fri Jul 19 2024, market cap of Biocept Inc is 183.82 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIOC stock?

You can check BIOC's fair value in chart for subscribers.

Is Biocept Inc a good stock to buy?

The fair value guage provides a quick view whether BIOC is over valued or under valued. Whether Biocept Inc is cheap or expensive depends on the assumptions which impact Biocept Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIOC.

What is Biocept Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, BIOC's PE ratio (Price to Earnings) is -0.01 and Price to Sales (PS) ratio is 0.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIOC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Biocept Inc's stock?

In the past 10 years, Biocept Inc has provided -0.607 (multiply by 100 for percentage) rate of return.